Arpida sells iclaprim to Acino and prepares for Evolva merger
This article was originally published in Scrip
Executive Summary
Arpida has sold its diaminopyrimidine antibiotic iclaprim to fellow Swiss firm Acino for CHF2.1 million ($2.05 million). Development of the drug, which Arpida licensed from Roche and was developing under the name Mersarex, ran aground after the EU's CHMP issued a negative opinion last month (scripnews.com, October 26th, 2009). In the US, the FDA issued a complete response letter requiring further clinical trials which the company deemed to be too costly. An earlier FDA panel had recommended against its approval saying that Arpida had failed to show non-inferiority to linezolid (Pfizer's Zyvox).
You may also be interested in...
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.